MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ZTS stock logo

ZTS

Zoetis Inc.

$117.89
0.6
 (0.51%)
Exchange:  NYSE
Market Cap:  51.953B
Shares Outstanding:  478.128M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Kristin C. Peck
Full Time Employees:  13800
Address: 
10 Sylvan Way
Parsippany
NJ
7054
US
Website:  https://www.zoetis.com
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/06 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue8,544,0009,256,0009,467,000
Gross Profit5,834,0006,396,0006,673,000
EBITDA3,685,0003,872,0004,069,000
Operating Income3,069,0003,392,0003,597,000
Net Income2,344,0002,486,0002,673,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets14,286,00014,237,00015,467,000
Total Liabilities9,295,0009,467,00012,136,000
Total Stockholders Equity4,997,0004,770,0003,331,000
Total Debt6,755,0006,744,000196,000
Cash and Cash Equivalents2,039,0001,985,0002,312,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,353,0002,953,0002,904,000
Capital Expenditure-732,000-655,000-621,000
Free Cash Flow1,621,0002,298,0002,283,000
Net Income2,344,0002,496,0002,673,000
Net Change in Cash-1,540,000-54,000325,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)11,713,577.091Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)12,052,926.195Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)11,858,500Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)5,296,532.975Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)5,449,976.599Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)5,362,062.827Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)4,048,982.440Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)4,202,043.378Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)4,114,350.459Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)2,950,286.876Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)3,035,758.393Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)2,986,788.463Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)9.270Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)9.470Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)9.120Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
9.256B  ?P/S
 (TTM)
: 
5.26
?Net Income
 (TTM)
: 
2.486B  ?P/E
 (TTM)
: 
19.32
?Enterprise Value
 (TTM)
: 
56.935B  ?EV/FCF
 (TTM)
: 
24.94
?Dividend Yield
 (TTM)
: 
0.02  ?Payout Ratio
 (TTM)
: 
0.33
?ROE
 (TTM)
: 
0.58  ?ROIC
 (TTM)
: 
0.22
?Net Debt
 (TTM)
: 
4.808B  ?Debt/Equity
 (TTM)
: 
2.85
?P/B
 (TTM)
: 
15.5  ?Current Ratio
 (TTM)
: 
3.03

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
16.79Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates ZTS intrinsic value between $74.34 – $166.84 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ZTS Intrinsic Value

Common questions about ZTS valuation

Is Zoetis Inc. (ZTS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Zoetis Inc. (ZTS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ZTS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ZTS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ZTS’s P/E ratio?

You can see ZTS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ZTS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ZTS a good long-term investment?

Whether ZTS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ZTS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

0.51
MARKETSnap

Trading Metrics:

Open: 115.93   Previous Close: 117.29
Day Low: 115.37   Day High: 118.65
Year Low: 113.29   Year High: 172.23
Price Avg 50: 122.94   Price Avg 200: 136.3
Volume: 1.479M   Average Volume: 4.3M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Zoetis (ZTS) Declines More Than Market: Some Information for Investors
10-04-2026 19:16
Zoetis (ZTS) Declines More Than Market: Some Information for Investors
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
22-01-2026 13:11
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis Inc. $ZTS Shares Sold by Ascent Group LLC
07-04-2026 03:30
Zoetis Inc. $ZTS Shares Sold by Ascent Group LLC
Zoetis: Still Not Cheap Near 5-Year Lows
02-04-2026 15:35
Zoetis: Still Not Cheap Near 5-Year Lows
Beacon Investment Advisory Services Inc. Sells 137,722 Shares of Zoetis Inc. $ZTS
31-03-2026 03:34
Beacon Investment Advisory Services Inc. Sells 137,722 Shares of Zoetis Inc. $ZTS
Zoetis (ZTS) Falls More Steeply Than Broader Market: What Investors Need to Know
27-03-2026 19:15
Zoetis (ZTS) Falls More Steeply Than Broader Market: What Investors Need to Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read